25 April 2008 - Latest phase II data for Boehringer Ingelheim’s new cancer drug in development presented- Monotherapy treatment with the triple angiokinase inhibitor1 BIBF 1120 (planned tradename Vargatef ™) offers promising efficacy and is well tolerated in patients with advanced, relapsed non-small cell lung cancer (NSCLC), according to results from a phase II study in patients with lung cancer2. Of particular note were results from a subset of 57 patients with ‘good disease state’ (ECOG performance status* of 0 or 1): these patients experienced longer overall survival (median overall survival was 9.5 months), longer progression-free survival (PFS; median PFS was 2.9 months) and a higher stable disease rate of 59% compared with the overall study population. The results were presented today by Dr Joachim von Pawel from Asklepios Fachkliniken München-Gauting, Germany, at the 1st European Lung Cancer Conference jointly organized by IASLC and ESMO in Geneva, Switzerland... Boehringer Ingelheim's Press Release -May 5, 2008
Boehringer Ingelheim : Data suggests promising overall survival and progression-free survival with Vargatef (BIBF 1120)
25 April 2008 - Latest phase II data for Boehringer Ingelheim’s new cancer drug in development presented- Monotherapy treatment with the triple angiokinase inhibitor1 BIBF 1120 (planned tradename Vargatef ™) offers promising efficacy and is well tolerated in patients with advanced, relapsed non-small cell lung cancer (NSCLC), according to results from a phase II study in patients with lung cancer2. Of particular note were results from a subset of 57 patients with ‘good disease state’ (ECOG performance status* of 0 or 1): these patients experienced longer overall survival (median overall survival was 9.5 months), longer progression-free survival (PFS; median PFS was 2.9 months) and a higher stable disease rate of 59% compared with the overall study population. The results were presented today by Dr Joachim von Pawel from Asklepios Fachkliniken München-Gauting, Germany, at the 1st European Lung Cancer Conference jointly organized by IASLC and ESMO in Geneva, Switzerland... Boehringer Ingelheim's Press Release -
